Literature DB >> 8274734

Alterations of the p53 tumor suppressor gene in diffuse large cell lymphomas with translocations of the c-MYC and BCL-2 proto-oncogenes.

M M Farrugia1, L J Duan, M D Reis, B Y Ngan, N L Berinstein.   

Abstract

Diffuse large cell lymphomas are aggressive tumors of B-cell origin. In some cases they arise from low-grade follicular lymphomas carrying the t(14;18) translocation, an event that leads to the overexpression of the BCL-2 gene product. More frequently, however, they lack the t(14;18) translocation. Rearrangements of the c-MYC proto-oncogene and mutations of the p53 tumor suppressor gene have also been documented in these lymphomas. This study examines the extent to which alterations in the BCL-2, c-MYC, and p53 genes co-exist within individual lymphomas. Eight diffuse large cell lymphoma cell lines and 11 diffuse large cell lymphoma tumors were assessed for genetic alterations in these three genes. Our results indicate that there is a heterogeneity in the oncogene/suppressor gene profile among diffuse large cell lymphomas. Two cell lines and one tumor carried alterations in all three genes, one cell line carried alterations of c-MYC and p53, and one primary tumor and one cell line carried p53 mutations and the t(14;18). Single alterations of BCL-2 and p53 were also observed. Another cell line had no alterations in any of these genes. The heterogeneity indicates that varied mechanisms may be involved in the generation of diffuse large cell lymphomas.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8274734

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  12 in total

1.  An oxidative stress-based mechanism of doxorubicin cytotoxicity suggests new therapeutic strategies in ABC-DLBCL.

Authors:  Yun Mai; J Jessica Yu; Boris Bartholdy; Zijun Y Xu-Monette; Esther E Knapp; Fei Yuan; Hongshan Chen; B Belinda Ding; Zhihua Yao; Bhaskar Das; Yiyu Zou; Ken He Young; Samir Parekh; B Hilda Ye
Journal:  Blood       Date:  2016-10-13       Impact factor: 22.113

2.  Inhibition of proliferation and survival of diffuse large B-cell lymphoma cells by a small-molecule inhibitor of the ubiquitin-conjugating enzyme Ubc13-Uev1A.

Authors:  Mary Pulvino; Yue Liang; David Oleksyn; Michael DeRan; Elise Van Pelt; Joel Shapiro; Ignacio Sanz; Luojing Chen; Jiyong Zhao
Journal:  Blood       Date:  2012-07-12       Impact factor: 22.113

3.  Gene set enrichment analysis unveils the mechanism for the phosphodiesterase 4B control of glucocorticoid response in B-cell lymphoma.

Authors:  Sang-Woo Kim; Deepak Rai; Ricardo C T Aguiar
Journal:  Clin Cancer Res       Date:  2011-07-08       Impact factor: 12.531

4.  Rapid high-resolution mapping of balanced chromosomal rearrangements on tiling CGH arrays.

Authors:  Harvey A Greisman; Noah G Hoffman; Hye Son Yi
Journal:  J Mol Diagn       Date:  2011-09-09       Impact factor: 5.568

5.  Microarray analysis of B-cell lymphoma cell lines with the t(14;18).

Authors:  Ryan S Robetorye; Sandra D Bohling; John W Morgan; G Chris Fillmore; Megan S Lim; Kojo S J Elenitoba-Johnson
Journal:  J Mol Diagn       Date:  2002-08       Impact factor: 5.568

6.  De novo CD5-positive and Richter's syndrome-associated diffuse large B cell lymphomas are genotypically distinct.

Authors:  A Matolcsy; A Chadburn; D M Knowles
Journal:  Am J Pathol       Date:  1995-07       Impact factor: 4.307

7.  Sequential transcription factor targeting for diffuse large B-cell lymphomas.

Authors:  Leandro C Cerchietti; Jose M Polo; Gustavo F Da Silva; Pedro Farinha; Rita Shaknovich; Randy D Gascoyne; Steven F Dowdy; Ari Melnick
Journal:  Cancer Res       Date:  2008-05-01       Impact factor: 12.701

8.  Inhibition of bromodomain proteins for the treatment of human diffuse large B-cell lymphoma.

Authors:  Sally E Trabucco; Rachel M Gerstein; Andrew M Evens; James E Bradner; Leonard D Shultz; Dale L Greiner; Hong Zhang
Journal:  Clin Cancer Res       Date:  2014-07-09       Impact factor: 12.531

9.  CC-122, a pleiotropic pathway modifier, mimics an interferon response and has antitumor activity in DLBCL.

Authors:  Patrick R Hagner; Hon-Wah Man; Celia Fontanillo; Maria Wang; Suzana Couto; Mike Breider; Chad Bjorklund; Courtney G Havens; Gang Lu; Emily Rychak; Heather Raymon; Rama Krishna Narla; Leo Barnes; Gody Khambatta; Hsiling Chiu; Jolanta Kosek; Jian Kang; Michael D Amantangelo; Michelle Waldman; Antonia Lopez-Girona; Ti Cai; Michael Pourdehnad; Matthew Trotter; Thomas O Daniel; Peter H Schafer; Anke Klippel; Anjan Thakurta; Rajesh Chopra; Anita K Gandhi
Journal:  Blood       Date:  2015-05-22       Impact factor: 22.113

10.  A model of sensitivity and resistance to histone deacetylase inhibitors in diffuse large B cell lymphoma: Role of cyclin-dependent kinase inhibitors.

Authors:  Ana A Tula-Sanchez; Aaron P Havas; Peter J Alonge; Mary E Klein; Samantha R Doctor; William Pinkston; Betty J Glinsmann-Gibson; Lisa M Rimsza; Catharine L Smith
Journal:  Cancer Biol Ther       Date:  2013-08-02       Impact factor: 4.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.